Investor Overview

Corporate Profile

Selecta Biosciences is a clinical-stage biopharmaceutical company developing  targeted immunotherapies and vaccines that are designed to modulate immune responses to treat and prevent disease. Selecta’s proprietary Synthetic Vaccine Particle (SVP™) platform has the potential to create a new paradigm in immunology and may enable a novel approach for selectively targeting the immune system to effectively and safely treat and prevent rare and serious diseases... View more »

Recent News
View all press releases »
Download DocumentationAug 04, 2016
BioWorld - Tolerizing nanoparticles could broaden the scope of biologics
Upcoming Events
Oct 28, 2016
Eighth Annual Immunogenicity and Bioassay Summit
remind me days before the event
Nov 11, 2016
American College of Rheumatology Annual Meeting
remind me days before the event
Dec 07, 2016
Eleventh Annual IMVACS: Immunization and Vaccine Summit
remind me days before the event
Enter your e-mail address 
View all events »
Stock Quote
NASDAQ GS :  SELB (Common Stock)
- 0.28 (0.00%)
Stock chart for: SELB.O.  Currently trading at $16.41 with a 52 week high of $18.88 and a 52 week low of $10.26.
Data as of Oct 24, 2016 4:00 p.m. ET
Minimum 15 minute delay
Refresh quote
IR Contact
Stephanie Ascher
Stern Investor Relations, Inc.
Phone: 1 212 362 1200

Data provided by Nasdaq. Minimum 15 minutes delayed.
Back to Top